Matthew E. Lipman - Feb 14, 2025 Form 3 Insider Report for Capstone Holding Corp. (CAPS)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Matthew E. Lipman
Stock symbol
CAPS
Transactions as of
Feb 14, 2025
Transactions value $
$0
Form type
3
Date filed
4/22/2025, 03:53 PM
Previous filing
Dec 10, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CAPS Common Stock 2.65M Feb 14, 2025 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CAPS Common Stock Warrants Feb 14, 2025 Common Stock 6.32K $75.00 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of (i) 121,774 shares controlled by Matthew Lipman, through his control of BP Peptides, LLC. Brookstone Acquisition Partners XXI Corporation owns 81% of BP Peptides, LLC. Mr. Lipman owns approximately 4% of Brookstone Acquisition Partners XXI Corporation; and (ii) 2,528,662 shares of Common Stock owned by BPA XIV, LLC, an entity controlled by Matthew Lipman.
F2 Includes a warrant to purchase up to 6,322 shares of Common Stock issued to Brookstone Partners IAC, Inc., the investment manager of BP Peptides, LLC which is controlled by Matthew Lipman and Michael Toporek.